$3.08 Billion is the total value of Avidity Partners Management LP's 96 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LLY | New | LILLY ELI & CO | $136,845,000 | – | 810,500 | +100.0% | 4.44% | – |
| AZN | New | ASTRAZENECA PLCsponsored adr | $114,977,000 | – | 2,300,000 | +100.0% | 3.73% | – |
| MRVI | New | MARAVAI LIFESCIENCES HLDGS I | $96,654,000 | – | 3,445,772 | +100.0% | 3.14% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $87,067,000 | – | 992,900 | +100.0% | 2.83% | – |
| STTK | New | SHATTUCK LABS INC | $49,203,000 | – | 938,813 | +100.0% | 1.60% | – |
| ARNA | New | ARENA PHARMACEUTICALS INC | $47,711,000 | – | 621,000 | +100.0% | 1.55% | – |
| CCXI | New | CHEMOCENTRYX INC | $46,873,000 | – | 757,000 | +100.0% | 1.52% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $44,663,000 | – | 521,100 | +100.0% | 1.45% | – |
| CAH | New | CARDINAL HEALTH INC | $43,276,000 | – | 808,000 | +100.0% | 1.40% | – |
| ORGO | New | ORGANOGENESIS HLDGS INC | $41,577,000 | – | 5,521,500 | +100.0% | 1.35% | – |
| BHC | New | BAUSCH HEALTH COS INC | $41,018,000 | – | 1,972,000 | +100.0% | 1.33% | – |
| XLRN | New | ACCELERON PHARMA INC | $38,254,000 | – | 299,000 | +100.0% | 1.24% | – |
| SRPT | New | SAREPTA TEHRAPEUTICS INC | $37,065,000 | – | 217,400 | +100.0% | 1.20% | – |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $34,813,000 | – | 147,300 | +100.0% | 1.13% | – |
| SGTX | New | SIGILON THERAPEUTICS INC | $33,045,000 | – | 688,000 | +100.0% | 1.07% | – |
| EXAS | New | EXACT SCIENCES CORP | $32,725,000 | – | 247,000 | +100.0% | 1.06% | – |
| CRDF | New | CARDIFF ONCOLOGY INC | $28,910,000 | – | 1,607,000 | +100.0% | 0.94% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $28,755,000 | – | 300,000 | +100.0% | 0.93% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $28,205,000 | – | 527,600 | +100.0% | 0.92% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $26,916,000 | – | 240,000 | +100.0% | 0.87% | – |
| ATEC | New | ALPHATEC HLDGS INC | $26,875,000 | – | 1,850,873 | +100.0% | 0.87% | – |
| ATRC | New | ATRICURE INC | $24,862,000 | – | 446,600 | +100.0% | 0.81% | – |
| SHC | New | SOTERA HEALTH CO | $19,208,000 | – | 700,000 | +100.0% | 0.62% | – |
| CRIS | New | CURIS INC | $19,182,000 | – | 2,342,100 | +100.0% | 0.62% | – |
| SIBN | New | SI BONE INC | $19,133,000 | – | 639,884 | +100.0% | 0.62% | – |
| BLU | New | BELLUS HEALTH INC NEW | $17,522,000 | – | 5,726,000 | +100.0% | 0.57% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $17,057,000 | – | 965,300 | +100.0% | 0.55% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $16,483,000 | – | 303,000 | +100.0% | 0.54% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $15,538,000 | – | 125,690 | +100.0% | 0.50% | – |
| SGRY | New | SURGERY PARTNERS INC | $15,404,000 | – | 531,000 | +100.0% | 0.50% | – |
| CERT | New | CERTARA INC | $13,645,000 | – | 404,663 | +100.0% | 0.44% | – |
| STRO | New | SUTRO BIOPHARMA INC | $13,590,000 | – | 626,000 | +100.0% | 0.44% | – |
| CDXS | New | CODEXIS INC | $13,098,000 | – | 600,000 | +100.0% | 0.42% | – |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $12,982,000 | – | 270,000 | +100.0% | 0.42% | – |
| ONCS | New | ONCOSEC MED INC | $12,590,000 | – | 1,952,000 | +100.0% | 0.41% | – |
| KURA | New | KURA ONCOLOGY INC | $11,354,000 | – | 347,645 | +100.0% | 0.37% | – |
| CSTL | New | CASTLE BIOSCIENCES INC | $10,073,000 | – | 150,000 | +100.0% | 0.33% | – |
| SCYX | New | SCYNEXIS INC | $9,601,000 | – | 1,255,000 | +100.0% | 0.31% | – |
| GRTS | New | GRITSTONE ONCOLOGY INC | $8,361,000 | – | 2,122,064 | +100.0% | 0.27% | – |
| IGMS | New | IGM BIOSCIENCES INC | $7,063,000 | – | 80,000 | +100.0% | 0.23% | – |
| LGND | New | LIGAND PHARMACEUTICALS INC | $6,176,000 | – | 62,100 | +100.0% | 0.20% | – |
| COGT | New | COGENT BIOSCIENCES INC | $5,836,000 | – | 519,645 | +100.0% | 0.19% | – |
| BLSA | New | BCLS ACQUISITION CORP | $5,570,000 | – | 500,000 | +100.0% | 0.18% | – |
| ARYA | New | ARYA SCIENCES ACQUISITION CO | $5,425,000 | – | 500,000 | +100.0% | 0.18% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $5,175,000 | – | 250,000 | +100.0% | 0.17% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $5,103,000 | – | 300,000 | +100.0% | 0.17% | – |
| PHAT | New | PHATHOM PHARMACEUTICALS INC | $5,066,000 | – | 152,500 | +100.0% | 0.16% | – |
| ALBO | New | ALBIREO PHARMA INC | $4,689,000 | – | 125,000 | +100.0% | 0.15% | – |
| HLXA | New | HELIX ACQUISITION CORP | $4,548,000 | – | 400,000 | +100.0% | 0.15% | – |
| LSAQ | New | LIFESCI ACQUISITION II CORP | $4,268,000 | – | 400,000 | +100.0% | 0.14% | – |
| KROS | New | KEROS THERAPEUTICS INC | $2,822,000 | – | 40,000 | +100.0% | 0.09% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $2,742,000 | – | 50,000 | +100.0% | 0.09% | – |
| BCAB | New | BIOATLA INC | $1,701,000 | – | 50,000 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.